首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1871509

2021-2031年亞太地區人類微生物組市場報告：範圍、細分、動態和競爭分析

Asia Pacific Human Microbiome Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis

出版日期: 2025年09月01日 | 出版商:

The Insight Partners | 英文 138 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

預計亞太地區人類微生物組市場將顯著成長，到 2031 年將達到約 7.0384 億美元，高於 2023 年的 1.241 億美元，在此期間複合年複合成長率(CAGR) 將達到 24.2%。

執行摘要和市場分析

市場分為多個區域，包括澳洲、中國、印度、日本、韓國以及亞太其他地區。推動該市場成長的關鍵因素包括代謝紊亂盛行率的上升、基因突變研究和藥物開發需求的增加，以及市場參與者之間的策略合作。此外，旨在提高公眾對人類微生物組認知的政府措施和資金投入也進一步推動了市場擴張。

市場區隔

亞太地區人類微生物組市場可以透過類型、應用和疾病類型等多個細分市場進行分析。

類型：市場分為產品和軟體/服務兩大類，其中產品類在 2023 年佔據主導地位。該類市場可進一步細分為益生菌和益生元。
應用領域：市場分為治療、診斷和研究三個部分，其中治療領域在 2023 年佔據最大的市場佔有率。
疾病類型：市場也按疾病類型細分，包括肥胖症、糖尿病、自體免疫疾病、癌症、胃腸道 (GIT) 問題等，其中 GIT 細分市場在 2023 年佔據市場佔有率領先地位。

市場展望

人類微生物組在醫療保健領域具有革命性變革的潛力，這促使相關研發投資激增。微生物組由數兆棲息於人體內外的微生物組成，在維持健康和預防疾病方面發揮著至關重要的作用。生技新創公司和製藥公司正加大對以微生物組為基礎的療法研發的投入。例如，印度領先的微生物組新創公司之一Xome Life Sciences，致力於開發利用微生物組資料改善健康狀況的診斷和治療工具。

此外，Seres Therapeutics公司針對復發性艱難梭菌感染的治療方案已獲得FDA批准，展現了基於微生物組的藥物的巨大治療潛力。像Vedanta Biosciences這樣的公司也在籌集大量資金，用於開發源自微生物組的免疫療法，以治療自體免疫疾病和癌症等疾病。包括Seventure Partners和Flagship Pioneering在內的知名投資者正在積極支持分析微生物組資料的公司，這凸顯了人們對微生物組在健康領域重要性的日益重視。預計這股投資熱潮將推動精準醫療和治療介入的進步，並在市場中創造眾多機會。

國家概況

亞太地區人類微生物組市場涵蓋中國、日本、印度、澳洲、韓國等主要國家，其中中國在2023年佔據最大的市場佔有率。新藥研發、產品改進和策略合作等因素顯著推動了中國微生物組療法市場的發展。例如，人工智慧驅動的微生物組療法公司Xbiome Inc.收購了Assembly Biosciences的一個臨床階段項目，該項目專注於開發針對乙型肝炎等病毒性疾病的創新療法。

目標疾病盛行率的不斷上升預計將進一步刺激人類微生物組市場的成長。研究不斷揭示微生物組在多種健康狀況中的關鍵作用，從而引發了人們對基於微生物組的療法的濃厚興趣，尤其是在胃腸道疾病、自體免疫疾病和代謝性疾病方面。微生物組療法有望提供更有效、更個人化的治療方案，這為市場成長開闢了廣闊前景。根據美國國立衛生研究院（NIH）的數據顯示，中國腸躁症（IBS）的盛行率在2.3%至15.8%之間，顯示該領域存在巨大的市場機會。

公司簡介

人類微生物組市場的主要參與者包括 MaaT Pharma、Ferring Holdings SA、AOBiome Therapeutics Inc、Finch Therapeutics Group Inc、Seres Therapeutics Inc、Merck & Co Inc、Rebiotix, Inc.、Yakult Honsha Co., Ltd.、IFF Nutrition & Biosciences 和 Synthetic Biologics, Inc.。這些公司正在採用各種策略，包括擴張、產品創新以及併購，以增強其產品供應並提高市場佔有率。

The market is divided into several regions, including Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Key drivers of growth in this market include the rising prevalence of metabolic disorders, an increasing demand for research in gene mutation and drug development, and strategic collaborations among market participants. Additionally, government initiatives and funding aimed at enhancing awareness of the human microbiome are further propelling market expansion.

Market Segmentation

The Asia Pacific human microbiome market can be analyzed through various segments, including type, application, and disease type.

Type: The market is categorized into products and software/services, with the product segment dominating in 2023. This segment is further divided into probiotics and prebiotics.
Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
Disease Type: The market is also segmented by disease type, including obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with the GIT segment leading in market share in 2023.

Market Outlook

The human microbiome's potential to revolutionize healthcare has led to a surge in investments in research and development. The microbiome, consisting of trillions of microorganisms residing in and on the human body, plays a crucial role in maintaining health and preventing diseases. Biotech startups and pharmaceutical companies are increasingly funding the development of microbiome-based therapies. For instance, Xome Life Sciences, one of India's pioneering microbiome startups, is focused on creating diagnostic and therapeutic tools that leverage microbiome data to enhance health outcomes.

Moreover, Seres Therapeutics has received FDA approval for a treatment targeting recurrent Clostridium difficile infections, showcasing the therapeutic potential of microbiome-based drugs. Companies like Vedanta Biosciences are also raising significant funds to develop immunotherapies derived from microbiomes for conditions such as autoimmune disorders and cancer. Notable investors, including Seventure Partners and Flagship Pioneering, are actively supporting companies that analyze microbiome data, highlighting the growing recognition of the microbiome's importance in health. This influx of investment is expected to drive advancements in precision medicine and therapeutic interventions, creating numerous opportunities within the market.

Country Insights

The Asia Pacific human microbiome market includes key countries such as China, Japan, India, Australia, South Korea, and others, with China holding the largest market share in 2023. Factors such as new pharmaceutical developments, product enhancements, and strategic partnerships are significantly benefiting the microbiome therapies market in China. For example, Xbiome Inc., an AI-driven microbiome therapeutics company, has acquired a clinical-stage program from Assembly Biosciences, which is focused on innovative treatments for viral disorders like hepatitis B.

The increasing prevalence of target disorders is expected to further stimulate growth in the human microbiome market. Research continues to uncover the microbiome's critical role in various health conditions, leading to a heightened interest in microbiome-based therapies, particularly for gastrointestinal disorders, autoimmune diseases, and metabolic disorders. The potential for microbiome therapeutics to offer more effective and personalized treatment options presents a promising avenue for market growth. According to the National Institute of Health, the prevalence of Irritable Bowel Syndrome (IBS) in China ranges from 2.3% to 15.8%, indicating a significant market opportunity.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase market share.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macroeconomic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country-level data:

4. Asia Pacific Human Microbiome Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Significant Investments by Key Market Players
- 4.1.2 Government Initiatives
4.2 Market Restraints
- 4.2.1 Challenges During Production of Microbiome
4.3 Market Opportunities
- 4.3.1 Robust Investment in Research and Development
4.4 Future Trends
- 4.4.1 Emergence of Precision Medicine
4.5 Impact of Drivers and Restraints:

5. Human Microbiome Market - Asia Pacific Analysis

5.1 Asia Pacific Human Microbiome Market Revenue (US$ Million), 2021-2031
5.2 Asia Pacific Human Microbiome Market Forecast Analysis

6. Asia Pacific Human Microbiome Market Analysis - by Type

6.1 Product
- 6.1.1 Overview
- 6.1.2 Product: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
6.2 Software and Services
- 6.2.1 Overview
- 6.2.2 Software and Services: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

7. Asia Pacific Human Microbiome Market Analysis - by Application

7.1 Therapeutics
- 7.1.1 Overview
- 7.1.2 Therapeutics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.2 Diagnostics
- 7.2.1 Overview
- 7.2.2 Diagnostics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Research
- 7.3.1 Overview
- 7.3.2 Research: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

8. Asia Pacific Human Microbiome Market Analysis - by Disease Type

8.1 Obesity
- 8.1.1 Overview
- 8.1.2 Obesity: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Diabetes
- 8.2.1 Overview
- 8.2.2 Diabetes: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Autoimmune Disorder
- 8.3.1 Overview
- 8.3.2 Autoimmune Disorder: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Cancer
- 8.4.1 Overview
- 8.4.2 Cancer: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.5 GIT
- 8.5.1 Overview
- 8.5.2 GIT: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)

9. Asia Pacific Human Microbiome Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Human Microbiome Market Overview
- 9.1.2 Asia Pacific Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.1 Asia Pacific Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 9.1.2.2 China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.2.1 China: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.2.2 China: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.2.3 China: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.2.4 China: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.3 Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.3.1 Japan: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.3.2 Japan: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.3.3 Japan: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.3.4 Japan: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.4 India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.4.1 India: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.4.2 India: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.4.3 India: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.4.4 India: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.5 Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.5.1 Australia: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.5.2 Australia: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.5.3 Australia: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.5.4 Australia: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.6 South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.6.1 South Korea: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.6.2 South Korea: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.6.3 South Korea: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.6.4 South Korea: Asia Pacific Human Microbiome Market Share - by Disease Type
  - 9.1.2.7 Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 9.1.2.7.1 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Type
    - 9.1.2.7.2 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Product
    - 9.1.2.7.3 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Application
    - 9.1.2.7.4 Rest of APAC: Asia Pacific Human Microbiome Market Share - by Disease Type

10. Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Human Microbiome Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 MaaT Pharma
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Ferring Holdings SA
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 AOBiome Therapeutics Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Finch Therapeutics Group Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Financial Overview
- 11.4.4 SWOT Analysis
- 11.4.5 Key Developments
11.5 Seres Therapeutics Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Merck & Co Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Yakult Honsha Co., Ltd.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Rebiotix, Inc.
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 IFF Nutrition & Biosciences
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Synthetic Biologics, Inc.
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 Glossary of Terms
12.2 About The Insight Partners

簡介目錄圖表

List Of Tables

Table 1. Asia Pacific Human Microbiome Market Segmentation
Table 2. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Table 3. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Type
Table 4. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Application
Table 5. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Disease Type
Table 6. Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million) - by Country
Table 7. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 8. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 9. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 10. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 11. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 12. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 13. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 14. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 15. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 16. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 17. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 18. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 19. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 21. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 22. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 23. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 24. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 25. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 26. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 27. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 28. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product
Table 29. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 30. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Disease Type
Table 31. Recent Organic Growth Strategies in the Human Microbiome Market
Table 32. Recent Inorganic Growth Strategies in the Human Microbiome Market
Table 33. Glossary of Terms, Human Microbiome Market

List Of Figures

Figure 1. Asia Pacific Human Microbiome Market Segmentation - Country
Figure 2. Asia Pacific Human Microbiome Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Human Microbiome Market Revenue (US$ Million), 2021-2031
Figure 5. Asia Pacific Human Microbiome Market Share (%) - by Type (2023 and 2031)
Figure 6. Product: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 7. Software and Services: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 8. Asia Pacific Human Microbiome Market Share (%) - by Application (2023 and 2031)
Figure 9. Therapeutics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 10. Diagnostics: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 11. Research: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 12. Asia Pacific Human Microbiome Market Share (%) - by Disease Type (2023 and 2031)
Figure 13. Obesity: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 14. Diabetes: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 15. Autoimmune Disorder: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 16. Cancer: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 17. GIT: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 18. Others: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021-2031 (US$ Million)
Figure 19. Asia Pacific Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 20. China: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 21. Japan: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 22. India: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 23. Australia: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 24. South Korea: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 25. Rest of APAC: Asia Pacific Human Microbiome Market - Revenue and Forecast, 2021- 2031 (US$ Million)
Figure 26. Growth Strategies in the Human Microbiome Market